D
Diane Solomon
Researcher at National Institutes of Health
Publications - 140
Citations - 25253
Diane Solomon is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Cervical intraepithelial neoplasia & Cervical cancer. The author has an hindex of 66, co-authored 140 publications receiving 23979 citations. Previous affiliations of Diane Solomon include United States Department of Health and Human Services & University of New Mexico.
Papers
More filters
Journal ArticleDOI
The 2001 Bethesda System: terminology for reporting results of cervical cytology.
Diane Solomon,Diane D. Davey,Robert J. Kurman,Marianne U. Prey,Stephen S. Raab,Mark E. Sherman,David C. Wilbur,Nancy A. Young +7 more
TL;DR: The 2001 Bethesda System terminology reflects important advances in biological understanding of cervical neoplasia and cervical screening technology.
Journal ArticleDOI
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
Steven A. Rosenberg,Beverly S. Packard,Paul Aebersold,Diane Solomon,Suzanne L. Topalian,S T Toy,P Simon,Michael T. Lotze,James Chih-Hsin Yang,Claudia A. Seipp +9 more
TL;DR: It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells.
Journal ArticleDOI
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer
Debbie Saslow,Diane Solomon,Herschel W. Lawson,Maureen Killackey,Shalini L Kulasingam,Joanna M. Cain,Francisco A.R. Garcia,Ann T. Moriarty,Alan G. Waxman,David C. Wilbur,Nicolas Wentzensen,Levi S. Downs,Mark Spitzer,Anna-Barbara Moscicki,Eduardo L. Franco,Mark H. Stoler,Mark Schiffman,Philip E. Castle,Evan R. Myers +18 more
TL;DR: An update to the ACS guideline regarding screening for the early detection of cervical precancerous lesions and cancer is presented, addressing age‐appropriate screening strategies, including the use of cytology and high‐risk human papillomavirus (HPV) testing.
Journal ArticleDOI
Comparison of Three Management Strategies for Patients With Atypical Squamous Cells of Undetermined Significance: Baseline Results From a Randomized Trial
TL;DR: HC 2 testing for cancer-associated HPV DNA is a viable option in the management of women with ASCUS and has greater sensitivity to detect CIN3 or above and specificity comparable to a single additional cytologic test indicating ASCUS or above.
Journal ArticleDOI
2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests
Thomas C. Wright,L. Stewart Massad,Charles J. Dunton,Mark Spitzer,Edward J. Wilkinson,Diane Solomon +5 more
TL;DR: The 2004 Interim Guidance for HPV testing as an adjunct to cervical cytology for screening in women 30 years of age and older was formally adopted with only very minor modifications.